Astra Aktiebolag

Astrazeneca Ab

Lars-Erik Briggner

Eva A Trofast

Jan W Trofast

Edib Jakupovic

Hans Lönn

Per Tomas Klingstedt

Andrew James Watts

Katarina Bystrom

Robert Zuban

Marie-Lyne Alcaraz

Robert Anthony Nixon

Hans Roland Lönn

Helena Nicklasson

6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.

Salt 628

There are described finely divided particles of a pharmaceutical substance, wherein the substance when submitted to water vapor gives off heat of less than 1.2 Joules per gram, processes for their production and pharmaceutical formulations containing them.

Pharmaceutical formulation

Process for conditioning substances

The present invention relates to a process for providing a stable crystallinic form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such a substance or a substance mixture, by

Micro formoterol particles

Growing community of inventors

Lund, Sweden

Lars-Erik Briggner